Literature DB >> 11424016

Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks.

J A Buxton1, D M Skowronski, H Ng, S A Marion, Y Li, A King, J Hockin.   

Abstract

The antibody response to a single influenza vaccination and the effect of influenza revaccination was assessed in healthy elderly persons. Travelers > or =65 years old who had received influenza vaccine before travel were enrolled in the study and were offered a second vaccination after 12 weeks. Geographic and age-matched control subjects received a single vaccination. A second influenza vaccination was not associated with increased adverse effects. There was no significant difference between log(10) hemagglutinin-inhibiting (HI) antibody titers or an HI antibody titer > or =1:40 (considered to be protective) in 28 control subjects and 28 revaccinated travelers for any antigen. Probable protection for influenza A antigens remained high 24 weeks after a single immunization and revaccination (A/Sydney/05/97 [H3N2], 92% and 96%, and A/Beijing/262/95 [H1N1], 80% and 96%, respectively). Response to B/Harbin was less throughout the study. A/Sydney antibody titer was lower with more times vaccinated in the previous 5 years. Therefore, a second vaccine did not enhance the immune response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11424016     DOI: 10.1086/322013

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Three-year (1999-2002) of epidemiological and virological surveillance of influenza in north-east Italy.

Authors:  F Ansaldi; P D'Agaro; P Burgnich; D de Florentiis; S Favero; G Dal Molin; M Comar; N Coppola; C Campello
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

2.  Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years.

Authors:  Iman Almansour; Huaiqing Chen; Shixia Wang; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2013-07-24       Impact factor: 3.452

3.  Statement on Seasonal Influenza Vaccine for 2011-2012: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-14

4.  Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-08-31

5.  STATEMENT ON SEASONAL INFLUENZA VACCINE FOR 2012-2013: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2012-08-01

6.  Statement on Seasonal Influenza Vaccine for 2013-2014: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2013-10-10

7.  Lack of persistence of influenza vaccine antibody titers in patients with heart failure.

Authors:  Caroline M Albrecht; Nancy K Sweitzer; Maryl R Johnson; Orly Vardeny
Journal:  J Card Fail       Date:  2013-12-19       Impact factor: 5.712

8.  Recent Advances and New Challenges in Travel Medicine.

Authors:  Lin H. Chen; Mary E. Wilson
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.663

9.  2011-12 seasonal influenza vaccines effectiveness against confirmed A(H3N2) influenza hospitalisation: pooled analysis from a European network of hospitals. A pilot study.

Authors:  Marc Rondy; Joan Puig-Barbera; Odile Launay; Xavier Duval; Jesús Castilla; Marcela Guevara; Simona Costanzo; Katleen de Gaetano Donati; Alain Moren
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

Review 10.  Vaccines for preventing influenza in the elderly.

Authors:  Vittorio Demicheli; Tom Jefferson; Carlo Di Pietrantonj; Eliana Ferroni; Sarah Thorning; Roger E Thomas; Alessandro Rivetti
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.